Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.06) by 966.67 percent. This is a 5.88 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $288.127 million which missed the analyst consensus estimate of $289.720 million by 0.55 percent. This is a 55.23 percent increase over sales of $185.618 million the same period last year.